Disease Markers / 2019 / Article / Tab 8

Research Article

Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals

Table 8

The association between the ADRB3 rs4994 genotype and the risk of NAFLD in normal-weight and overweight/obese subjects, as determined using 5,000 randomly sampled data sets.

Weight statusADRB3 genotypeNAFLDOR [95% CI] value
AbsentPresent

Normal-weightT/T1357 (82.3)292 (17.7)1
T/C687 (76.5)211 (23.5)1.38 [1.12–1.70]<0.01
C/C88 (80.7)21 (19.3)1.38 [0.82–2.32]0.22

Overweight/obeseT/T1169 (81.5)266 (18.5)1
T/C635 (78.6)173 (21.4)1.16 [0.93–1.46]0.183
C/C62 (61.4)39 (38.6)3.26 [2.08–5.12]<0.001

OverweightT/T990 (81.2)229 (18.8)1
T/C538 (78.7)146 (21.3)1.14 [0.89–1.45]0.30
C/C52 (59.8)35 (40.2)3.76 [2.31–6.13]<0.01

ADRB3: beta-3-adrenergic receptor; NAFLD: nonalcoholic fatty liver disease; BMI: body mass index; OR: odds ratio; CI: confidence interval; NAFLD: nonalcoholic fatty liver disease. Data are the number (%). Adjusted by age, BMI, diabetes, and dyslipidemia. Analyzed using a logistic regression analysis.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.